8QFA | pdb_00008qfa

Solution structure of the extreme C-terminus of the Bordetella pertussis filamentous hemagglutinin prodomain

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D 1H-15N HSQC	0.5 mM [U-13C; U-15N] FHA-ECT, 137 mM sodium chloride, 2.7 mM potassium chloride, 10 mM disodium phosphate, 1.8 mM monopotassium phosphate, 0.1 % sodium azide, 90 % v/v H2O, 10 % v/v [U-2H] D2O	90% H2O/10% D2O	171.5 mM	7.4	1 atm	298	Bruker AVANCE III 700
2	2D 1H-13C HSQC	0.5 mM [U-13C; U-15N] FHA-ECT, 137 mM sodium chloride, 2.7 mM potassium chloride, 10 mM disodium phosphate, 1.8 mM monopotassium phosphate, 0.1 % sodium azide, 90 % v/v H2O, 10 % v/v [U-2H] D2O	90% H2O/10% D2O	171.5 mM	7.4	1 atm	298	Bruker AVANCE III 700
3	3D HNCACB	0.5 mM [U-13C; U-15N] FHA-ECT, 137 mM sodium chloride, 2.7 mM potassium chloride, 10 mM disodium phosphate, 1.8 mM monopotassium phosphate, 0.1 % sodium azide, 90 % v/v H2O, 10 % v/v [U-2H] D2O	90% H2O/10% D2O	171.5 mM	7.4	1 atm	298	Bruker AVANCE III 700
4	3D CBCA(CO)NH	0.5 mM [U-13C; U-15N] FHA-ECT, 137 mM sodium chloride, 2.7 mM potassium chloride, 10 mM disodium phosphate, 1.8 mM monopotassium phosphate, 0.1 % sodium azide, 90 % v/v H2O, 10 % v/v [U-2H] D2O	90% H2O/10% D2O	171.5 mM	7.4	1 atm	298	Bruker AVANCE III 700
5	3D HNCO	0.5 mM [U-13C; U-15N] FHA-ECT, 137 mM sodium chloride, 2.7 mM potassium chloride, 10 mM disodium phosphate, 1.8 mM monopotassium phosphate, 0.1 % sodium azide, 90 % v/v H2O, 10 % v/v [U-2H] D2O	90% H2O/10% D2O	171.5 mM	7.4	1 atm	298	Bruker AVANCE III 700
6	3D HN(CA)CO	0.5 mM [U-13C; U-15N] FHA-ECT, 137 mM sodium chloride, 2.7 mM potassium chloride, 10 mM disodium phosphate, 1.8 mM monopotassium phosphate, 0.1 % sodium azide, 90 % v/v H2O, 10 % v/v [U-2H] D2O	90% H2O/10% D2O	171.5 mM	7.4	1 atm	298	Bruker AVANCE III 700
7	3D HNCA	0.5 mM [U-13C; U-15N] FHA-ECT, 137 mM sodium chloride, 2.7 mM potassium chloride, 10 mM disodium phosphate, 1.8 mM monopotassium phosphate, 0.1 % sodium azide, 90 % v/v H2O, 10 % v/v [U-2H] D2O	90% H2O/10% D2O	171.5 mM	7.4	1 atm	298	Bruker AVANCE III 700
8	3D HN(CO)CA	0.5 mM [U-13C; U-15N] FHA-ECT, 137 mM sodium chloride, 2.7 mM potassium chloride, 10 mM disodium phosphate, 1.8 mM monopotassium phosphate, 0.1 % sodium azide, 90 % v/v H2O, 10 % v/v [U-2H] D2O	90% H2O/10% D2O	171.5 mM	7.4	1 atm	298	Bruker AVANCE III 700
9	3D (H)CC(CO)NH	0.5 mM [U-13C; U-15N] FHA-ECT, 137 mM sodium chloride, 2.7 mM potassium chloride, 10 mM disodium phosphate, 1.8 mM monopotassium phosphate, 0.1 % sodium azide, 90 % v/v H2O, 10 % v/v [U-2H] D2O	90% H2O/10% D2O	171.5 mM	7.4	1 atm	298	Bruker AVANCE III 700
10	3D H(CCO)NH	0.5 mM [U-13C; U-15N] FHA-ECT, 137 mM sodium chloride, 2.7 mM potassium chloride, 10 mM disodium phosphate, 1.8 mM monopotassium phosphate, 0.1 % sodium azide, 90 % v/v H2O, 10 % v/v [U-2H] D2O	90% H2O/10% D2O	171.5 mM	7.4	1 atm	298	Bruker AVANCE III 700
11	3D HCCH-TOCSY	0.5 mM [U-13C; U-15N] FHA-ECT, 137 mM sodium chloride, 2.7 mM potassium chloride, 10 mM disodium phosphate, 1.8 mM monopotassium phosphate, 0.1 % sodium azide, 90 % v/v H2O, 10 % v/v [U-2H] D2O	90% H2O/10% D2O	171.5 mM	7.4	1 atm	298	Bruker AVANCE III 700
12	3D HCCH-TOCSY aromatic	0.5 mM [U-13C; U-15N] FHA-ECT, 137 mM sodium chloride, 2.7 mM potassium chloride, 10 mM disodium phosphate, 1.8 mM monopotassium phosphate, 0.1 % sodium azide, 90 % v/v H2O, 10 % v/v [U-2H] D2O	90% H2O/10% D2O	171.5 mM	7.4	1 atm	298	Bruker AVANCE III 700
13	2D (HB)CB(CGCD)HD	0.5 mM [U-13C; U-15N] FHA-ECT, 137 mM sodium chloride, 2.7 mM potassium chloride, 10 mM disodium phosphate, 1.8 mM monopotassium phosphate, 0.1 % sodium azide, 90 % v/v H2O, 10 % v/v [U-2H] D2O	90% H2O/10% D2O	171.5 mM	7.4	1 atm	298	Bruker AVANCE III 700
14	2D (HB)CB(CGCDCE)HE	0.5 mM [U-13C; U-15N] FHA-ECT, 137 mM sodium chloride, 2.7 mM potassium chloride, 10 mM disodium phosphate, 1.8 mM monopotassium phosphate, 0.1 % sodium azide, 90 % v/v H2O, 10 % v/v [U-2H] D2O	90% H2O/10% D2O	171.5 mM	7.4	1 atm	298	Bruker AVANCE III 700
15	3D 1H-15N NOESY	0.5 mM [U-13C; U-15N] FHA-ECT, 137 mM sodium chloride, 2.7 mM potassium chloride, 10 mM disodium phosphate, 1.8 mM monopotassium phosphate, 0.1 % sodium azide, 90 % v/v H2O, 10 % v/v [U-2H] D2O	90% H2O/10% D2O	171.5 mM	7.4	1 atm	298	Bruker AVANCE III 700
16	3D 1H-13C NOESY aliphatic	0.5 mM [U-13C; U-15N] FHA-ECT, 137 mM sodium chloride, 2.7 mM potassium chloride, 10 mM disodium phosphate, 1.8 mM monopotassium phosphate, 0.1 % sodium azide, 90 % v/v H2O, 10 % v/v [U-2H] D2O	90% H2O/10% D2O	171.5 mM	7.4	1 atm	298	Bruker AVANCE III 700
17	3D 1H-13C NOESY aromatic	0.5 mM [U-13C; U-15N] FHA-ECT, 137 mM sodium chloride, 2.7 mM potassium chloride, 10 mM disodium phosphate, 1.8 mM monopotassium phosphate, 0.1 % sodium azide, 90 % v/v H2O, 10 % v/v [U-2H] D2O	90% H2O/10% D2O	171.5 mM	7.4	1 atm	298	Bruker AVANCE III 700

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE III	700

NMR Refinement
Method	Details	Software
simulated annealing		RECOORD

NMR Ensemble Information
Conformer Selection Criteria	structures with the lowest energy
Conformers Calculated Total Number	250
Conformers Submitted Total Number	10
Representative Model	1 (lowest energy)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	chemical shift assignment	NMRFAM-SPARKY	1.2	Lee, Tonelli, Markley
2	structure calculation	ARIA	2.3.2	Linge, O'Donoghue and Nilges
7	structure calculation	CNS	1.3	Brunger, Adams, Clore, Gros, Nilges and Read
3	refinement	RECOORD		Nederveen, Doreleijers, Vranken, Miller, Spronk, Nabuurs, Guntert, Livny, Markley, Nilges, Ulrich, Kaptein, Bonvin
4	peak picking	NMRFAM-SPARKY	1.2	Lee, Tonelli, Markley
5	collection	TopSpin	3.5.7	Bruker Biospin
6	processing	NMRPipe		Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.